At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CAI Caris Life Sciences, Inc.
Post-Mkt 09-21 19:13:25 EDT
30.65
+0.67
+2.23%
盘后30.49
-0.16-0.52%
18:53 EDT
High30.71Low29.97Vol6.14M
Open30.23D1 Closing29.98Amplitude2.47%
Mkt Cap8.65BTradable Cap3.56BTotal Shares282.15M
T/O187.24MT/O Rate5.29%Tradable Shares116.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Caris Life Sciences Vice Chairman Brian J. Brille Disposes of 400,000 Common Shares for $12.13 Million
Reuters  ·  09-18
Caris Life Sciences Vice Chairman Brian J. Brille Disposes of 400,000 Common Shares for $12.13 Million
Movement Alert｜Caris Life Sciences, Inc. Rises 5.35% in Regular Trading, Earnings Beat and Institutional Coverage Continue to Boost Sentiment
Market Focus  ·  09-17
Movement Alert｜Caris Life Sciences, Inc. Rises 5.35% in Regular Trading, Earnings Beat and Institutional Coverage Continue to Boost Sentiment
CAI Corp Switches Auditor as Business Expansion Drives Greater Audit Demands
TIPRANKS  ·  09-17
CAI Corp Switches Auditor as Business Expansion Drives Greater Audit Demands
Movement Alert｜Caris Life Sciences, Inc. Rises 5.82% in Regular Trading, UBS Initiates Coverage Amid Strong Earnings Momentum
Market Focus  ·  09-16
Movement Alert｜Caris Life Sciences, Inc. Rises 5.82% in Regular Trading, UBS Initiates Coverage Amid Strong Earnings Momentum
CAI Corp reports unaudited net asset value of HK$0.16 per share
TIPRANKS  ·  09-15
CAI Corp reports unaudited net asset value of HK$0.16 per share
Caris Life Sciences, Inc. : UBS Initiates Coverage with Neutral Rating and Target Price $28
THOMSON REUTERS  ·  09-09
Caris Life Sciences, Inc. : UBS Initiates Coverage with Neutral Rating and Target Price $28
UBS Initiates Coverage on Caris Life Sciences With Neutral Rating, $28 Price Target
MT Newswires Live  ·  09-09
UBS Initiates Coverage on Caris Life Sciences With Neutral Rating, $28 Price Target
U.S. Research Roundup-Argan, Mastec, Oracle
Reuters  ·  09-09
U.S. Research Roundup-Argan, Mastec, Oracle
Caris Life Sciences President David Baxley Spetzler Disposes of USD 14.75 Million in Common Shares
Reuters  ·  09-05
Caris Life Sciences President David Baxley Spetzler Disposes of USD 14.75 Million in Common Shares
Caris Life Sciences to present new research at IASCL 2026
TIPRANKS  ·  09-02
Caris Life Sciences to present new research at IASCL 2026
Movement Alert｜Caris Life Sciences, Inc. Falls 5.19% in Regular Trading, Trading at $26.54
Market Focus  ·  08-26
Movement Alert｜Caris Life Sciences, Inc. Falls 5.19% in Regular Trading, Trading at $26.54
Movement Alert｜Caris Life Sciences, Inc. Rises 5.01% in Regular Trading, Trading at $27.44
Market Focus  ·  08-26
Movement Alert｜Caris Life Sciences, Inc. Rises 5.01% in Regular Trading, Trading at $27.44
Movement Alert｜Caris Life Sciences, Inc. Rises 5.09% in Regular Trading, Q2 Revenue Beats Estimates by 10.7% Fueling Continued Rally
Market Focus  ·  08-21
Movement Alert｜Caris Life Sciences, Inc. Rises 5.09% in Regular Trading, Q2 Revenue Beats Estimates by 10.7% Fueling Continued Rally
Movement Alert｜Caris Life Sciences, Inc. Rises 7.89% in Regular Trading, Q2 Revenue Beat Continues to Fuel Upward Momentum
Market Focus  ·  08-21
Movement Alert｜Caris Life Sciences, Inc. Rises 7.89% in Regular Trading, Q2 Revenue Beat Continues to Fuel Upward Momentum
CAI Corp Updates Market on Unaudited Net Asset Value Per Share
TIPRANKS  ·  08-14
CAI Corp Updates Market on Unaudited Net Asset Value Per Share
Caris Life Sciences Price Target Raised to $33.00/Share from $32.00 by BTIG
Dow Jones  ·  08-07
Caris Life Sciences Price Target Raised to $33.00/Share from $32.00 by BTIG
Analysts Are Bullish on These NA Stocks: Harrow Health (HROW), Caris Life Sciences, Inc. (CAI)
TIPRANKS  ·  08-07
Analysts Are Bullish on These NA Stocks: Harrow Health (HROW), Caris Life Sciences, Inc. (CAI)
Natera Q2 Revenue Rises Beats Estimates on Higher Overall Test Volumes, Raises 2026 Outlook
Reuters  ·  08-07
Natera Q2 Revenue Rises Beats Estimates on Higher Overall Test Volumes, Raises 2026 Outlook
Caris Life Sciences up over 15%, on Pace for Record Percent Increase
Dow Jones  ·  08-06
Caris Life Sciences up over 15%, on Pace for Record Percent Increase
Lantheus Q2 Revenue Rises 2.7%, Beats Estimates
Reuters  ·  08-06
Lantheus Q2 Revenue Rises 2.7%, Beats Estimates

Introduction

Company Name.
Caris Life Sciences, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Caris Life Sciences, Inc. is a leading patient-centered next-generation artificial intelligence technology biology company and precision medicine pioneer. It develops and commercializes innovative solutions to transform health care through the large-scale use of comprehensive molecular information and AI/ML algorithms. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology and serving the clinical, academic and biopharmaceutical markets.
Issue price:
--